Corbus Pharmaceuticals Holdings Inc
CRBP
Get informed when a big investor buys or sells
+ FollowMarket Cap$192.32M
Close$
$2.02
80% downside
Current Fair Value
80% downsideOvervalued by 80% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $192.32 Million |
|---|---|
| Enterprise Value | $173.21 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.9 |
| Beta | 2.62 |
| Outstanding Shares | 19,407,688 |
Return
| Return on Equity | -99.67% |
|---|---|
| Return on Assets | -80.25% |
| Return on Invested Capital | -22.91% |
Valuation & Multiples
| P/E Ratio | -1.6 |
|---|---|
| PEG | -1.63 |
| Price to Sales | - |
| Price to Book Ratio | 2.02 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -7.17 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-1.26
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-1.21
Average shareholder expectationRevenue Estimate
$1.67 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Corbus Pharmaceuticals Holdings, Inc.
28 employees
CEO: Dr. Yuval Cohen Ph.D. Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid...